Patents by Inventor Chunshan Gui

Chunshan Gui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3D-structure model of SARS coronavirus 3CL protease and anti-SARS drugs
    Patent number: 7662860
    Abstract: The present invention discloses 3D-structure of SARS-CoV Viral 3CL Protease obtained through molecular simulation. The 3D-structure is used as a drug target for screening the existing medical database CMC (Comprehensive Medicinal Chemistry, MDL Information System, Inc.), and a group of compounds which have the activity of inhibiting SARS-CoV virus 3CL Protease are found. Cinanserin was tested at molecular and viral levels, and it was found to be able to inhibit the SARS-CoV viral 3CL protease and SARS-CoV viruses. Cinanserin analogs were synthesized and tested at molecular and viral levels, they were found to be able to inhibit the SARS-CoV virus 3CL Protease and SARS-CoV viruses, and may be used for treating and/or preventing SARS-CoV virus infection.
    Type: Grant
    Filed: December 2, 2005
    Date of Patent: February 16, 2010
    Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai Lead Discovery Pharmaceuticals Limited Company
    Inventors: Jianhua Shen, Hualiang Jiang, Xu Shen, Jianping Zuo, Xiaomin Luo, Donglu Bai, Jingkang Shen, Kaixian Chen, Chunshan Gui, Lili Chen, Jing Chen, Yifu Yang, Xianhan Zhuang, Yiming Yang, Xuchang He, Hong Liu, Bing Xiong, Haibin Luo, Tao Sun, Fei Ye
  • 3D-Structure model of SARS coronavirus 3CL protease and anti-SARS drugs
    Publication number: 20060142383
    Abstract: The present invention discloses 3D-structure of SARS-CoV Viral 3CL Protease obtained through molecular simulation. The 3D-structure is used as a drug target for screening the existing medical database CMC (Comprehensive Medicinal Chemistry, MDL Information System, Inc.), and a group of compounds which have the activity of inhibiting SARS-CoV virus 3CL Protease are found. Cinanserin was tested at molecular and viral levels, and it was found to be able to inhibit the SARS-CoV viral 3CL protease and SARS-CoV viruses. Cinanserin analogs were synthesized and tested at molecular and viral levels, they were found to be able to inhibit the SARS-CoV virus 3CL Protease and SARS-CoV viruses, and may be used for treating and/or preventing SARS-CoV virus infection.
    Type: Application
    Filed: December 2, 2005
    Publication date: June 29, 2006
    Inventors: Jianhua Shen, Hualiang Jiang, Xu Shen, Jianping Zuo, Xiaomin Luo, Donglu Bai, Jingkang Shen, Kaixian Chen, Chunshan Gui, Lili Chen, Jing Chen, Yifu Yang, Xianhan Zhuang, Yiming Yang, Xuchang He, Hong Liu, Bing Xiong, Haibin Luo, Tao Sun, Fei Ye